Is Gilteritinib effective?

Gilitinib is a targeted therapy drug mainly used to treat FLT3 gene mutation subtypes in patients with acute myeloid leukemia (Acute Myeloid Leukemia, AML). FLT3 gene mutations are relatively common in AML, accounting for about 30% of cases, so the research and clinical trial results of giritinib have attracted widespread attention. The RATIFY trial evaluated the efficacy of giritinib in patients with newly diagnosed FLT3-ITD mutant AML. The trial results showed that patients in the geritinib treatment group had significantly better progression-free survival (PFS) than the standard chemotherapy group. The median PFS was longer in the geritinib group, suggesting that it can prolong disease control. In addition, overall survival improved in the giritinib group.